{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:48:15Z","timestamp":1772261295438,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41391-022-00541-6","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T12:03:33Z","timestamp":1650283413000},"page":"331-337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors\u2009\u00b1\u2009androgen deprivation therapy: a pharmacovigilance study"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6406-5784","authenticated-orcid":false,"given":"Logan G.","family":"Briggs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Reese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David-Dan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4580-1915","authenticated-orcid":false,"given":"Muhieddine","family":"Labban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6008-0503","authenticated-orcid":false,"given":"Khalid","family":"Alkhatib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quoc-Dien","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-4587","authenticated-orcid":false,"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"541_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA: A Cancer J Clinicians. 2021;71:7\u201333.","journal-title":"CA: A Cancer J Clinicians"},{"key":"541_CR2","first-page":"103","volume":"360","author":"M Bolla","year":"2002","unstructured":"Bolla M, Collette L, Blank L, Warde P, Dubois JB. Mirimanoff R-o et al. Bolla 2002 pdf 2002;360:103\u20138.","journal-title":"Bolla 2002 pdf"},{"key":"541_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0090-4295(02)01560-1","volume":"60","author":"MV Meng","year":"2002","unstructured":"Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology. 2002;60:7\u201311.","journal-title":"Urology"},{"key":"541_CR4","doi-asserted-by":"publisher","first-page":"e196562","DOI":"10.1001\/jamanetworkopen.2019.6562","volume":"2","author":"R Jayadevappa","year":"2019","unstructured":"Jayadevappa R, Chhatre S, Malkowicz SB, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. JAMA Netw Open. 2019;2:e196562\u2013e196562.","journal-title":"JAMA Netw Open"},{"key":"541_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/aja.2011.107","volume":"14","author":"RJ Jamadar","year":"2012","unstructured":"Jamadar RJ, Winters MJ, Maki PM. Cognitive changes associated with ADT: a review of the literature. Asian J Androl. 2012;14:232\u20138.","journal-title":"Asian J Androl"},{"key":"541_CR6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.juro.2017.11.136","volume":"199","author":"M Sun","year":"2018","unstructured":"Sun M, Cole AP, Hanna N, Mucci LA, Berry DL, Basaria S, et al. Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2018;199:1417\u201325.","journal-title":"J Urol"},{"key":"541_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.urolonc.2019.01.021","volume":"38","author":"MM Cherrier","year":"2020","unstructured":"Cherrier MM, Higano CS. Impact of androgen deprivation therapy on mood, cognition, and risk for AD. Urologic Oncol: Semin Original Investig. 2020;38:53\u201361.","journal-title":"Urologic Oncol: Semin Original Investig"},{"key":"541_CR8","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/cncr.31153","volume":"124","author":"DJ McHugh","year":"2018","unstructured":"McHugh DJ, Root JC, Nelson CJ, Morris MJ. Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire? Cancer. 2018;124:1326\u201334.","journal-title":"Cancer"},{"key":"541_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/pcan.2017.10","volume":"20","author":"KT Nead","year":"2017","unstructured":"Nead KT, Sinha S, Nguyen PL. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017;20:259\u201364.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"541_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.euo.2019.08.003","volume":"4","author":"KH Tully","year":"2021","unstructured":"Tully KH, Nguyen D-D, Herzog P, Jin G, Noldus J, Nguyen PL, et al. Risk of dementia and depression in young and middle-aged men presenting with nonmetastatic prostate cancer treated with androgen deprivation therapy. Eur Urol Oncol. 2021;4:66\u201372.","journal-title":"Eur Urol Oncol"},{"key":"541_CR11","doi-asserted-by":"publisher","first-page":"103463","DOI":"10.1016\/j.critrevonc.2021.103463","volume":"166","author":"Z Bakouny","year":"2021","unstructured":"Bakouny Z, Yeked\u00fcz E, Braun DA, Berchuck JE, Hirsch L, Utkan G et al. Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: a systematic review and meta-analysis. Crit Rev in Oncol\/Hematol. 2021;166:103463.","journal-title":"Crit Rev in Oncol\/Hematol."},{"key":"541_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42:409\u201319.","journal-title":"Drug Inf J"},{"key":"541_CR13","unstructured":"Institute NC. Common terminology criteria for adverse events (CTCAE). NIH. 2017;5:1."},{"key":"541_CR14","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/pds.4246","volume":"26","author":"D Motola","year":"2017","unstructured":"Motola D, Donati M, Biagi C, Calamelli E, Cipriani F, Melis M, et al. Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase. Pharmacoepidemiol Drug Saf. 2017;26:1164\u201371.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"541_CR15","doi-asserted-by":"publisher","first-page":"100887","DOI":"10.1016\/j.eclinm.2021.100887","volume":"36","author":"EB Cone","year":"2021","unstructured":"Cone EB, Reese S, Marchese M, Nabi J, McKay RR, Kilbridge KL et al. Cardiovascular toxicities associated with abiraterone compared to enzalutamide\u2013A pharmacovigilance study. EClinicalMed. 2021;36:100887.","journal-title":"EClinicalMed."},{"key":"541_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jamadermatol.2020.3385","volume":"157","author":"DD Nguyen","year":"2021","unstructured":"Nguyen DD, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N, et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 2021;157:35\u201342.","journal-title":"JAMA Dermatol"},{"key":"541_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00408-021-00425-x","volume":"199","author":"SW Reese","year":"2021","unstructured":"Reese SW, Cone E, Marchese M, Garcia B, Chou W, Ayub A et al. Lessons from pharmacovigilance: pulmonary immune-related adverse events after immune checkpoint inhibitor therapy. Lung. 2021;199:199\u2013211.","journal-title":"Lung."},{"key":"541_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/bju.15059","volume":"126","author":"EB Cone","year":"2020","unstructured":"Cone EB, Marchese M, Reese SW, Sun M, Nabi J, Kilbridge K, et al. Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists. BJU Int. 2020;126:9\u201310.","journal-title":"BJU Int"},{"key":"541_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J-L Montastruc","year":"2011","unstructured":"Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"541_CR20","unstructured":"Ryan P, Simpson S, Zorych I, Madigan D. Bayesian methods in pharmacovigilance. Oxford University Press: Oxford, 2011."},{"key":"541_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/pros.21263","volume":"71","author":"WR Foster","year":"2011","unstructured":"Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate. 2011;71:480\u20138.","journal-title":"Prostate"},{"key":"541_CR22","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1200\/JCO.2014.60.1963","volume":"33","author":"BD Gonzalez","year":"2015","unstructured":"Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY, et al. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol. 2015;33:2021\u20137.","journal-title":"J Clin Oncol"},{"key":"541_CR23","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1200\/JCO.2017.72.6109","volume":"35","author":"SH Baik","year":"2017","unstructured":"Baik SH, Kury FSP, McDonald CJ. Risk of Alzheimer\u2019s disease among senior medicare beneficiaries treated with androgen deprivation therapy for prostate cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2017;35:3401\u20139.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"541_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1200\/JCO.2015.63.6266","volume":"34","author":"KT Nead","year":"2016","unstructured":"Nead KT, Gaskin G, Chester C, Swisher-McClure S, Dudley JT, Leeper NJ, et al. Androgen deprivation therapy and future Alzheimer\u2019s disease risk. J Clin Oncol. 2016;34:566\u201371.","journal-title":"J Clin Oncol"},{"key":"541_CR25","unstructured":"Stewart J. Xtandi FDA approval history. FDA History of Drugscom. 2012."},{"key":"541_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiology Drug Saf. 2004;13:519\u201323.","journal-title":"Pharmacoepidemiology Drug Saf"},{"key":"541_CR27","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1200\/JCO.2017.74.8806","volume":"35","author":"KT Nead","year":"2017","unstructured":"Nead KT. Androgen deprivation therapy and dementia: new opportunities and challenges in the big-data era. J Clin Oncol. 2017;35:3380\u20131.","journal-title":"J Clin Oncol"},{"key":"541_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/srep35695","volume":"6","author":"KT Nead","year":"2016","unstructured":"Nead KT, Gaskin G, Chester C, Swisher-McClure S, Dudley JT, Leeper NJ, et al. Influence of age on androgen deprivation therapy-associated Alzheimer\u2019s disease. Sci Rep. 2016;6:35695.","journal-title":"Sci Rep"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00541-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00541-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00541-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T13:04:53Z","timestamp":1686143093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00541-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["541"],"URL":"https:\/\/doi.org\/10.1038\/s41391-022-00541-6","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"20 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to disclose. QDT reports personal fees from Astellas, Bayer and Janssen, outside the submitted work. QDT reports research funding from the American Cancer Society, the Defense Health Agency, Pfizer Global Medical Grants. AKM reports personal fees from Astellas, AstraZeneca, Advanced Accelerator Applications, Bayer, Clovis, Dendreon, Exelixis, Myovant, Novartis, Pfizer, Sanofi, Blue Earth, Lantheus, and Myriad. LGB reports consulting fees from Delfina outside of the submitted work and research funding from the Office of Scholarly Engagement at Harvard Medical School. All other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}